Ovarian cancer prevention in Michigan

Most aggressive ovarian cancers begin in the Fallopian tubes.

This discovery has changed what prevention can look like. If you are already having abdominal or pelvic surgery, your surgeon may be able to remove both Fallopian tubes during the same operation - and cut your risk of the most aggressive ovarian cancers at least in half.

University of MichiganMichigan Surgical Quality CollaborativeCanary Foundation

What are the Fallopian tubes?

The Fallopian tubes are two thin passageways, each a few inches long, that connect the ovaries to the uterus. After an ovary releases an egg, the egg travels through a Fallopian tube toward the uterus. The tubes do not make hormones - that is the ovaries’ job.

What do the Fallopian tubes have to do with ovarian cancer?

For nearly two decades, research has shown that most high-grade serous ovarian cancers - the most common and most aggressive kind - do not actually start in the ovaries. They start at the open end of a Fallopian tube and spread to the ovary from there. And because there is no reliable screening test for ovarian cancer, it is usually found late, after it has spread.

Can removing the Fallopian tubes prevent cancer?

Removing both Fallopian tubes takes away the place where most of these cancers begin. Research estimates it cuts the risk at least in half - from about 11 in 1,000 to about 5 in 1,000 for an average-risk woman. The ovaries stay in place and keep making hormones, so tube removal has not been shown to change hormone levels or bring on earlier menopause.

When would this come up for me?

If you are already scheduled for abdominal or pelvic surgery - an appendix, bowel, or gynecologic operation, for example - your surgeon may be able to remove both Fallopian tubes during that same operation. It usually adds less than 15 minutes. One thing to know before anything else: it is permanent, and pregnancy is no longer possible afterward without in vitro fertilization. The choice is always yours.

The risk, in real numbers

Out of 1,000 average-risk women, about 11 develop ovarian cancer during their lifetime. Research estimates that removing both Fallopian tubes lowers that to about 5 in 1,000.

Removal does not eliminate all ovarian cancer risk. After both Fallopian tubes are removed, pregnancy is no longer possible without in vitro fertilization. The choice is always yours - the decision aid helps you think it through and does not recommend an option.

11 in 1,000

Average lifetime risk of ovarian cancer

About 5 in 1,000

Research estimate after both Fallopian tubes are removed

Each circle is one woman out of 1,000 at average risk. The estimate applies to the most aggressive (high-grade serous) ovarian cancers.

Education for patients. A program for clinicians.

For patients, this website is educational. The program itself works with Michigan providers to make the option available safely and consistently.

MI-MAGIC: Michigan Multi-Specialty Action for Gynecologic Innovation and Care

In partnership with

Outsmart Ovarian Cancer

Outsmart Ovarian Cancer is a national education initiative from the American Cancer Society and Break Through Cancer, built on the same science: preventing ovarian cancer by removing the Fallopian tubes, where it starts. MI-MAGIC brings that message to Michigan operating rooms. Their site offers fact sheets, videos, guidelines, and news for patients and clinicians.

Explore their patient resources →

What the research shows

Every number on this site comes from a named study. These three anchor the program.

56%

of women who developed high-grade serous ovarian cancer had an earlier abdominal or pelvic surgery where both Fallopian tubes could have been removed.

Tischer et al., Gynecologic Oncology, 2025 - 605 patients
30 years

passed, on average, between that earlier surgery and the cancer diagnosis. Prevention during surgery reaches women decades before the disease appears.

Tischer et al., Gynecologic Oncology, 2025 - median 30.0 years
200-300

opportunistic salpingectomies prevent one ovarian cancer over a 20 to 30 year horizon - in the same range as screening colonoscopy for colorectal cancer.

Wright et al., Annals of Surgery, 2025; NordICC trial, NEJM, 2022

Read the evidence in plain language →

A statewide program, built in phases

MI-MAGIC (Michigan Multi-Specialty Action for Gynecologic Innovation & Care) is a University of Michigan program supported by the Canary Foundation and a University of Michigan Frankel Award. It works with the Michigan Surgical Quality Collaborative and its 70 member hospitals to train surgeons, support hospitals, and measure results statewide.

About the program →

Plain-language evidence library

Summaries of the key studies behind the program, with sources named.

Available now
Ovarian cancer risk calculator

A validated tool for estimating personal risk and discussing prevention options.

In development
Michigan referral directory

Connections to gynecology, genetic counseling, and other prevention services.

Being designed
Patient and surgeon videos

Short educational videos and an Ask the Surgeon series.

In development
Translated materials

Spanish and additional Michigan-relevant languages, added after review.

Planned